DSM Venturing invests in purification technology company Upfront Chromatography
24 September 2007
DSM Venturing, the corporate venturing unit of Royal DSM N V, today announced having participated in an equity investment round in the Danish company Upfront Chromatography A/S, the world''s leading developer of customised industrial protein chromatography processes.
In addition to the investment, DSM and Upfront have signed a collaboration agreement with the aim of further developing the Rhobust technology for the purification of monoclonal antibodies.
DSM Venturing, which is an active investor in emerging companies and venture capital funds in its parents strategic growth fields of nutrition, pharma and performance materials, said in a communiqué, "The downstream processing platform developed by Upfront is of great potential to contribute to all biotechnology-derived products from DSM. DSM is joined in this investment round by financial investors InnovationsKapital and NBGI Ventures."
DSM
Venturing says its mission is to explore emerging markets and technologies in
these strategic growth fields in order to enhance DSM''s product portfolio and
create value. DSM Venturing also plays an active role in the development of several
new DSM business opportunities in the so-called emerging business areas biomedical,
industrial (white) biotechnology, specialty packaging and personalised nutrition.
DSM Pharmaceutical Products is a global provider of custom manufacturing services
to the pharmaceutical and biopharmaceutical industries with a broad menu of services
in protein production and in clinical, commercial and fill and finish areas.
The company''s achievements in biopharmaceutical production have resulted in a significant urgency in attaining breakthroughs in downstream processing, enabling more efficient purification of monoclonal antibodies and other biopharmaceutical proteins.
In addition to the investment, DSM and Upfront have signed a collaboration agreement with the aim of further developing the Rhobust technology for the purification of monoclonal antibodies.
